The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Review initially finds dolutegravir has no links to birth defects then revises its findings to report a ‘slightly higher’ – but minimal – incidence after two cases emerge
New research reveals high rates of loss to follow-up among adolescents, with rates among those acquiring the infection in their teens nearly three times that of those infected perinatally.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.
A new pill technology has the potential to simplify HIV treatment and curb the rise of drug-resistant HIV.